cineole	placebo	Trouble in breathing, dyspnea in the morning and dyspnea at rest	-1	-1	Trouble in breathing # <TAB> 1.8 ± 0.9 <TAB> 2.1 ± 0.9 <TAB> 2.2 ± 1.0 <TAB> 1.9 ± 0.9 <TAB> 2.4 ± 1.0 <TAB> 2.5 ± 1.1 <TAB> 0.0103&Dyspnea in the morning $ <TAB> 1.1 ± 0.7 <TAB> 0.9 ± 0.7 <TAB> 0.7 ± 0.7 <TAB> 1.1 ± 0.8 <TAB> 0.7 ± 0.7 <TAB> 0.5 ± 0.6 <TAB> 0.0466&Dyspnea at rest $ <TAB> 0.7 ± 0.7 <TAB> 0.4 ± 0.6 <TAB> 0.4 ± 0.6 <TAB> 0.6 ± 0.6 <TAB> 0.3 ± 0.5 <TAB> 0.3 ± 0.5 <TAB> 0.0156&
cineole	placebo	Quality of life	1537	1667	Improvement of lung function, dyspnea and quality of life as multiple criteria were statistically significant relative to placebo.
cineole	placebo	Mean of sum of number, duration and severity of exacerbations during 6 months of treatment	-1	-1	Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo* <TAB> PLACEBO <TAB> CINEOLE <TAB>  <TAB> SCORE <TAB> SCORE <TAB> P VALUE†Sum of exacerbations (number)# <TAB> 0.9 ± 1.46 <TAB> 0.4 ± 0.82 <TAB> 0.0069Sum of duration (days)# <TAB> 5.7 ± 8.9 <TAB> 4.0 ± 10.9 <TAB> 0.0210Sum of severity (score)# <TAB> 1.4 ± 2.2 <TAB> 0.8 ± 1.5 <TAB> 0.0242Summarized parameter(directional test) <TAB>  <TAB>  <TAB> 0.0120
cineole	placebo	change of FVC and VC	16897	17002	The difference concerning change of FVC and VC between both treatment groups was not clinically relevant.
cineole	placebo	Dyspnea during exercise	-1	-1	Dyspnea during exercise $ <TAB> 2.0 ± 0.6 <TAB> 1.8 ± 0.7 <TAB> 1.7 ± 0.8 <TAB> 2.0 ± 0.6 <TAB> 1.7 ± 0.7 <TAB> 1.5 ± 0.9 <TAB> 0.1252&
cineole	placebo	Side effects	22128	22338	The difference between the two treatment groups was neither clinically relevant nor statistically significant. Safety examinations of the global assessment showed no difference between the two treatment groups.
cineole	placebo	Side effects	22128	22238	The difference between the two treatment groups was neither clinically relevant nor statistically significant.
